<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920121-0101</DOCNO><DOCID>920121-0101.</DOCID><HL>   Financing Business:   Deprenyl Research Ltd.</HL><DATE>01/21/92</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   DEPLF</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DIVIDENDS (DIV)DRUG MANUFACTURERS (DRG)INITIAL STOCK OFFERINGS (INI)STOCK AND BOND REGISTRATIONS, PRICINGS (REG)STOCK MARKET, OFFERINGS (STK)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>DIVIDENDS (DIV)INITIAL PUBLIC OFFERINGS (INI)BOND AND STOCK REGISTRATIONS AND PRICINGS (REG)STOCK andamp; OTHER MARKET NEWS (STK)ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>CANADA (CN)NORTH AMERICA (NME)</RE><LP>   DEPRENYL RESEARCH Ltd., Toronto, said it plans to sell30.1% of its Deprenyl USA Inc. unit to U.S. and Canadianinvestors through an initial public offering. The Torontodrug marketing concern said it will issue 1,250,000 units at$12 each for total proceeds of $15 million. Each unit willconsist of two common shares and a warrant to buy anadditional common share at $9 a share for 15 months followingthe issue date. Deprenyl common rose $1 to $20 inover-the-counter trading yesterday. The company said proceedsof the issue will be used by Deprenyl USA to pursueregulatory approvals required to introduce its first product,a photodynamic anti-cancer treatment, to the U.S. market.Deprenyl also said it will distribute 112,000 shares ofDeprenyl USA to its shareholders as a dividend, payable Feb.21 to holders of record Feb. 7. Deprenyl said it currentlyhas a 76.2% stake in Deprenyl USA, with private investorsholding the remainder. The initial public offering willreduce its holding to 46.1%, the company said.</LP><TEXT/></DOC>